We are live on ! Find out more

enGene Therapeutics

ENGN

Market cap $122M

1.82 USD

-0.01

0.55%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

1.82

0.00

0%

1 day

-0.55%

5 days

-0.55%

1 month

1.68%

3 months

5.81%

6 months

-81.31%

Year to date

-79.44%

1 year

-63.6%

5 years

-90.9%

10 years

-90.9%

About: enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Employees: 82

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 90%

Negative 10%

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15 a.m. ET Format: Fireside Chat Morgan Stanley 24th Annual Global Healthcare Conference Date: Monday, September 14, 2026 Time: 7:00 a.m. ET Format: Fireside Chat H.

enGene to Participate in Upcoming Investor Conferences

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dr.

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk no.

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates. “Feedback from the urology community on the emerging detalimogene without surfactant profile, presented at the AUA meeting in May, supports our plan to await mature durability data in the second half of 2026 and m.

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

EnGene Therapeutics: The Selloff Creates An Opportunity

enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete response rate, underperforming competitors, but boasts a strong safety profile and Fast Track/RMAT status. Risks include FDA rejection and insurers declining coverage due to low efficacy, but current valuation implies limited further downside given the cash position.

EnGene Therapeutics: The Selloff Creates An Opportunity

See News Rankings

Price charts implemented using Lightweight Charts™